[1][2] It is administered intravaginally and is described as the first vaginal microbiome (VMB)-based live biotherapeutic product (LBP).
[2] The Centers for Disease Control and Prevention (CDC)'s Sexually Transmitted Infections Treatment Guidelines (2021) noted that intravaginal LACTIN-V produced a considerably lower recurrence of BV following initial antibiotic treatment with metronidazole in a randomized controlled trial.
[3][4] However, the guidelines also noted that LACTIN-V is not yet Food and Drug Administration (FDA)-approved or commercially available.
[1] It was originated by GyneLogix and is under development by Osel Inc., the National Institute of Allergy and Infectious Diseases, and other organizations.
You can help Wikipedia by expanding it.This drug article relating to the genito-urinary system is a stub.